Deep Immune Profiling of Nonchimeric Tolerance of Transplants in Nonhuman Primates
Deep Immune Profiling of Nonchimeric Tolerance of Transplants in Nonhuman Primates
批准号:
10353191
负责人:
Bernhard Josef Hering
金额:
$23.25万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-04-22 至 2024-03-31
关键词:
ApoptoticBehavior TherapyBiological MarkersBone MarrowCD4 Positive T LymphocytesCellsCellular AssayChromatinChronicClinical TrialsComputer AnalysisCytometryData SetEpigenetic ProcessFailureFoundationsFutureGenerationsGenomicsGoalsHumanImmuneImmunobiologyImmunosuppressionInfusion proceduresInvestigationKidney TransplantationLeadLeukocytesMHC Class I GenesMacacaMacaca mulattaMaintenanceMemoryMinnesotaModelingMolecularMonitorMononuclearPeripheralPersonsPhenotypePopulationPositioning AttributeProtocols documentationPublic HealthRegimenRegulatory T-LymphocyteReportingResourcesRiskRoleSamplingSorting - Cell MovementSpecificityT-LymphocyteTechniquesTestingToxic effectTranscriptTransplant RecipientsTransplantationTransplantation ToleranceTransposaseWorkbiomarker discoveryclinical translationdigitalexhaustexhaustiongraft vs host diseasehigh dimensionalityimprovedinsightisletislet allograftmultiple omicsnonhuman primatenovelpeptide Ipreventrecruitsingle cell analysisterminally differentiated effector memory (TEM) T cellstooltranscriptometranscriptome sequencingtranscriptomics
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Transplant (tx) tolerance would profoundly improve the lives of thousands of people who will receive tx in the
years ahead. Recently, we reported safe and consistent induction of long-term (>1 year) tolerance to islet
allografts in nonhuman primates (NHPs) with two peritx infusions of apoptotic donor leukocytes (ADLs) under
induction immunosuppression (IIS) (in part supported by U01-AI102463). While these findings are
unprecedented and suggest the possibility of nonchimeric tx tolerance in humans, further insight into the
mechanisms by which tolerance is induced and maintained will be required before clinical translation of the
protocol can be initiated. Owing to the progress made in the epigenetic, transcriptomic and cytometric profiling
of single cells and computational analyses of high-dimensional datasets, the contributions of distinct immune cell
subsets and the graft to tolerance can now be investigated with previously unimaginable explicitness.
Accordingly, the goal of the proposed studies is to harness these novel tools and existing samples to delineate
the critical factors and mechanisms responsible for tx tolerance induced by the ADLs+IIS regimen. To this end,
we have established techniques for i) tracking and sorting allospecific CD4+ T cells, ii) single-cell ATAC- & RNA-
sequencing of these sorted cells, iii) digital spatial profiling (DSP) of grafts and graft microenvironments, and iv)
mass cytometry profiling of circulating mononuclear cells with four macaque-validated CyTOF panels.
In Aim 1, we will dissect the molecular diversity of circulating allospecific CD4+ T cells from tolerant and
nontolerant tx recipients in an unbiased manner by single-cell ATAC & RNA sequencing, testing the hypothesis
that the ADLs+IIS regimen causes i) exhaustion, ii) failure to acquire a memory phenotype and iii) expansion
and activation of regulatory subsets in CD4+ T cells via epigenetic and transcriptomic alterations.
In Aim 2, we will leverage DSP to investigate the role of the graft in the maintenance of tx tolerance, testing the
hypothesis that ADLs+IIS alters intragraft transcriptomes of co-inhibitory and protective molecules that determine
immune cell recruitment to islet and kidney grafts and their survival.
In Aim 3, we will utilize high-dimensional CyTOF profiling of circulating mononuclear cells (MNCs) with existing
as well as novel multiomic-guided panels focused on exhausted/memory (Tex/mem) and regulatory (Treg and
Tr1) T cells, testing the hypothesis that the same key heterogeneous clusters among Tex, Treg and Tr1 cell
populations are associated with islet and kidney tx tolerance induced by ADLs+IIS.
The studies proposed herein will be the first to leverage the power of epigenetic, transcriptomic and cytometric
analyses of single cells for investigation of mechanisms of peripheral tx tolerance in NHPs. The datasets
generated and analyzed will present a resource for investigating the immunobiology of nonchimeric tolerance,
with implications for biomarker discovery and clinical translation of the ADLs+IIS regimen.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Apoptotic Donor Leukocytes to Promote Kidney Transplant Tolerance
-
批准号:10622209
-
项目类别:
-
资助金额:$97.14万
-
财政年份:2023
-
负责人:Bernhard Josef Hering
-
依托单位:
Deep Immune Profiling of Nonchimeric Tolerance of Transplants in Nonhuman Primates
-
批准号:10612925
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2022
-
负责人:Bernhard Josef Hering
-
依托单位:
Alloantigen Delivery Via ECDI-Fixed Cells For Tolerance To Monkey Islet Grafts
-
批准号:8518234
-
项目类别:
-
资助金额:$83.9万
-
财政年份:2012
-
负责人:Bernhard Josef Hering
-
依托单位:
Alloantigen Delivery Via ECDI-Fixed Cells For Tolerance To Monkey Islet Grafts
-
批准号:8400970
-
项目类别:
-
资助金额:$86.94万
-
财政年份:2012
-
负责人:Bernhard Josef Hering
-
依托单位:
Alloantigen Delivery Via ECDI-Fixed Cells For Tolerance To Monkey Islet Grafts
-
批准号:8706034
-
项目类别:
-
资助金额:$86.94万
-
财政年份:2012
-
负责人:Bernhard Josef Hering
-
依托单位:
HUMAN PANCREATIC ISLET CELL RESOURCES
-
批准号:7725862
-
项目类别:
-
资助金额:$90.2万
-
财政年份:2008
-
负责人:Bernhard Josef Hering
-
依托单位:
EFALIZUMAB (RAPTIVA) COMBINED WITH SIROLIMUS IN TYPE 1 DIABETIC ISLET ALLOGRAFT
-
批准号:7951730
-
项目类别:
-
资助金额:$1.35万
-
财政年份:2008
-
负责人:Bernhard Josef Hering
-
依托单位:
SCREENING PROCEDURE FOR ALLO-ISLET TRANSPLANTATION PROTOCOLS
-
批准号:7951667
-
项目类别:
-
资助金额:$1.43万
-
财政年份:2008
-
负责人:Bernhard Josef Hering
-
依托单位:
CIT-03: SINGLE-CENTER, OPEN-LABEL CLINICAL TRIAL OF THE EFFICACY OF PERITRANSPLA
-
批准号:7951709
-
项目类别:
-
资助金额:$0.88万
-
财政年份:2008
-
负责人:Bernhard Josef Hering
-
依托单位:
CLINICAL TRIAL: HOKT3g1 (ALA-ALA), SIROLIMUS AND LOW DOSE TACROLIMUS THERAPY IN
-
批准号:7951673
-
项目类别:
-
资助金额:$3.88万
-
财政年份:2008
-
负责人:Bernhard Josef Hering
-
依托单位:
HUMAN PANCREATIC ISLET CELL RESOURCES
-
批准号:7622002
-
项目类别:
-
资助金额:$89.28万
-
财政年份:2007
-
负责人:Bernhard Josef Hering
-
依托单位:
CTS-IPITA-IXA 2007 Joint Conference
-
批准号:7334658
-
项目类别:
-
资助金额:$0.6万
-
财政年份:2007
-
负责人:Bernhard Josef Hering
-
依托单位:
CIT-03: SINGLE-CENTER, OPEN-LABEL CLINICAL TRIAL OF THE EFFICACY OF PERITRANSPLA
-
批准号:7606098
-
项目类别:
-
资助金额:$0.04万
-
财政年份:2006
-
负责人:Bernhard Josef Hering
-
依托单位:
ISLET TRANSPLANTATION IN TYPE 1 DIABETIC PATIENTS USING THE EDMONTON PROTOCOL
-
批准号:7605963
-
项目类别:
-
资助金额:$0.05万
-
财政年份:2006
-
负责人:Bernhard Josef Hering
-
依托单位:
HUMAN PANCREATIC ISLET CELL RESOURCES
-
批准号:7360458
-
项目类别:
-
资助金额:$107.05万
-
财政年份:2006
-
负责人:Bernhard Josef Hering
-
依托单位:
ANTI-THYMOGLOBUMLIN, CYCLOSPORIN AND RAD IN ISLET TRANSPLANT
-
批准号:7605982
-
项目类别:
-
资助金额:$0.41万
-
财政年份:2006
-
负责人:Bernhard Josef Hering
-
依托单位:
SCREENING PROCEDURE FOR ALLO-ISLET TRANSPLANTATION PROTOCOLS
-
批准号:7606020
-
项目类别:
-
资助金额:$1.05万
-
财政年份:2006
-
负责人:Bernhard Josef Hering
-
依托单位:
HOKT3γ1 (ALA-ALA), SIROLIMUS AND LOW DOSE TACROLIMUS THERAPY IN TYPE 1 DIAB
-
批准号:7606031
-
项目类别:
-
资助金额:$0.67万
-
财政年份:2006
-
负责人:Bernhard Josef Hering
-
依托单位:
ANTI-THYMOGLOBUMLIN, CYCLOSPORIN AND RAD IN ISLET TRANSPLANT
-
批准号:7375899
-
项目类别:
-
资助金额:$8.03万
-
财政年份:2005
-
负责人:Bernhard Josef Hering
-
依托单位:
SCREENING PROCEDURE FOR ALLO-ISLET TRANSPLANTATION PROTOCOLS
-
批准号:7375961
-
项目类别:
-
资助金额:$0.93万
-
财政年份:2005
-
负责人:Bernhard Josef Hering
-
依托单位:
海外基金